OneSource Specialty Pharma Ltd's Q4FY25 Quarter Results
- 06 May 2025
Result Summary
- OneSource Specialty Pharma Ltd reported a 81.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were down by 68.1% QoQ and - - YoY.
- The net profit decreased 41.7% QoQ and - - YoY.
- The earnings per share (EPS) of OneSource Specialty Pharma Ltd declined at 9.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 75.78 | 397.96 | 0.00 | -81.0% | - |
Total Expenses | 115.93 | 363.93 | 0.00 | -68.1% | - |
Profit Before Tax | -40.17 | -66.50 | - | -39.6% | NaN% |
Tax | 0.00 | 2.35 | 0.00 | -100.0% | - |
Profit After Tax | -40.17 | -68.85 | 0.00 | -41.7% | - |
Earnings Per Share | -9.70 | -6.30 | 0.00 | 54.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
OneSource Specialty Pharma Ltd is a company operating in the pharmaceutical industry, focusing on specialized pharma products and services. As of now, specific details regarding its main products or recent developments are not available in the provided data. The company is presumed to be involved in the production and distribution of pharmaceutical products, given its industry classification. Information about any recent strategic moves, new product launches, or significant partnerships is not provided in the current dataset. Thus, further specifics about the company's operational scope or strategic direction remain unclear based on the information at hand.
Revenue
For the fourth quarter of fiscal year 2025 (Q4FY25), OneSource Specialty Pharma Ltd reported a total income of ₹75.78 crores. This represents a significant decrease of 81.0% compared to the preceding quarter (Q3FY25), where the total income was ₹397.96 crores. The year-over-year comparison with Q4FY24 is not available as the data for that period is marked as zero, indicating the possibility of either no reported income or missing data. Therefore, a direct year-over-year analysis cannot be conducted for total income. The substantial quarter-over-quarter decline in revenue highlights a notable change in the company's financial performance during the latest quarter.
Profitability
In Q4FY25, OneSource Specialty Pharma Ltd recorded a loss before tax amounting to ₹40.17 crores, which is a reduction in loss when compared to the ₹66.50 crores loss reported in Q3FY25. This represents a 39.6% decrease in the loss on a quarter-over-quarter basis. The company did not incur any tax expenses in Q4FY25, a complete reduction from the ₹2.35 crores in taxes paid in the previous quarter. Consequently, the profit after tax also stood at a loss of ₹40.17 crores for Q4FY25, improving from a loss of ₹68.85 crores in Q3FY25, marking a 41.7% decrease in loss. Earnings Per Share (EPS) for Q4FY25 was reported at -₹9.70, a deterioration from the -₹6.30 EPS in Q3FY25, highlighting a 54.0% increase in the negative value of EPS quarter-over-quarter.
Operating Metrics
The total expenses for OneSource Specialty Pharma Ltd in Q4FY25 were ₹115.93 crores, showing a significant decrease of 68.1% from Q3FY25, where expenses were reported at ₹363.93 crores. The substantial reduction in expenses correlates with the decrease in total income over the same period. No year-over-year comparison for expenses and other operating metrics is possible due to the lack of available data for Q4FY24. The financial data highlights a period of reduced operational scale, as evidenced by the decreases in both income and expenses, alongside improved losses before and after tax.
